News &amp; Updates

A pharmacy-specific, foundational HIV management education package can help improve pharmacist knowledge in HIV management and self-reported confidence in managing this specialty area, suggests a recent study.

Education package improves pharmacist knowledge, confidence on HIV management

Epilepsy ups maternal, perinatal risks in pregnant women

Pregnant women with epilepsy face considerably greater risk of severe morbidity as well as maternal and perinatal mortality, according to a study.

Epilepsy ups maternal, perinatal risks in pregnant women

Add-on dapagliflozin of no help in critically ill patients with acute organ dysfunction

In the treatment of critically ill patients with acute organ dysfunction, use of the SGLT-2 inhibitor dapagliflozin in addition to standard care does not appear to improve clinical outcomes, according to a study.

Add-on dapagliflozin of no help in critically ill patients with acute organ dysfunction

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

13 Aug 2024 by

A new patient achieves sustained HIV remission – the seventh in the world – following stem cell therapy for blood cancer and after stopping antiretroviral therapy (ART), adding to the roster of individuals with HIV who are inching their way towards a potential cure.

The next Berlin patient: 7th to join pool of HIV patients achieving sustained remission

Cytisinicline for vaping cessation turns in promising result in phase II trial

Treatment with cytisinicline for 12 weeks, in addition to behavioural support, is well tolerated and appears to help e-cigarette users to quit vaping, according to the results of the phase II ORCA-V1 trial.

Cytisinicline for vaping cessation turns in promising result in phase II trial

Dabrafenib plus trametinib boasts high pathological response for stage III melanoma

Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.

Dabrafenib plus trametinib boasts high pathological response for stage III melanoma

12 Aug 2024

First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC

12 Aug 2024 by

First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.

First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC

12 Aug 2024

SGLT2i‒GLP1ra combo reduces risk of heart failure, mortality

In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.

Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.

SGLT2i‒GLP1ra combo reduces risk of heart failure, mortality

12 Aug 2024

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women

12 Aug 2024 by

Zero HIV infections: Lenacapavir fulfils PURPOSE in cis women

12 Aug 2024

Prognosis for patients with HBV-related HCC better after tenofovir vs entecavir treatment

Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) appear to fare better with tenofovir than with entecavir, with a recent study showing that prognosis is better for those who have been treated with tenofovir.

Prognosis for patients with HBV-related HCC better after tenofovir vs entecavir treatment